We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Clinigen Group Plc | LSE:CLIN | London | Ordinary Share | GB00B89J2419 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 925.00 | 924.50 | 925.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMCLIN
RNS Number : 9620V
Clinigen Group plc
10 November 2017
10 November 2017
Issue of Equity
Clinigen Group plc (AIM: CLIN, the "Group") announces that it has made an application for the admission to trading on AIM of 2,186 ordinary shares of 0.1 pence each in the Group (the "New Ordinary Shares"), which have been issued to satisfy the exercise of share options and rank pari passu with the existing shares of the Group. Admission to trading on AIM of the New Ordinary Shares is anticipated to occur on 15 November 2017.
At admission the issued share capital of the Group will consist of 122,222,210 ordinary shares, with no shares held in treasury. The total number of voting rights in the Group will therefore be 122,222,210. This figure may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interests in, the Group under the Disclosure Guidance and Transparency Rules.
-Ends-
Contact details
Hot Features
Premium
Clinigen Group plc Tel: +44 (0) 1283
495010
Shaun Chilton, Group Chief
Executive Officer
Martin Abell, Group Chief
Financial Officer
Numis Securities Limited Tel: +44 (0) 20
7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Tom Ballard
(Corporate Broking)
RBC Capital Markets - Joint Tel: +44 (0) 20
Broker 7653 4000
Marcus Jackson / Elliot Thomas
/ Jack Wood
Instinctif Partners Tel: +44 (0) 20
7457 2020
Melanie Toyne-Sewell / Alex
Shaw / Deborah Bell Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
For more information, please visit www.clinigengroup.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEFSIFIAFWSELF
(END) Dow Jones Newswires
November 10, 2017 04:00 ET (09:00 GMT)
1 Year Clinigen Chart |
1 Month Clinigen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
